We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In addition to potential Alzheimer’s and Parkinson’s therapies, Shape said it may use its adeno-associated virus platform to help identify other gene therapy targets, including for rare diseases. Read More
South Korean conglomerate Samsung, which already manufactures Moderna’s COVID-19 vaccine, plans to increase its involvement in the biopharmaceuticals space. Read More
TTI-622 and TTI-621 are the only CD47-targeted molecules to show meaningful monotherapy activity and complete responses across multiple hematological malignancies, the companies said. Read More
Eli Lilly’s biologics division, Lilly Bio-Medicines, is splitting into two distinct units, one of which will focus entirely on approved and phase 3 drugs for pain and neurodegeneration — including Alzheimer’s disease. Read More
There’s no national shortage of the life-saving opiate antagonist naloxone — just a shortage of the free or cheap single-use vials that Pfizer has distributed by the millions since 2017. Read More